TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Month Study to Assess Safety and Efficacy of Meridia (Sibutramine Hydrochloride Monohydrate) 10 and 15 mg in Obese Adolescents
Brief Summary: The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.


Options:
A: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide
B: Intervention Type: DRUG; Name: sibutramine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Rosiglitazone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Program | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Lifestyle Program; Assigned to Arm(s): 3
D: Arm Label: Metformin, Standard exercise; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin and standard exercise | Arm Label: Placebo, Standard exercise; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo Standard exercise | Arm Label: Metformin, Intensive exercise; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin Intensive exercise | Arm Label: Placebo, Intensive exercise; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Intensive exercise | Intervention Type: DRUG; Name: Metformin and standard exercise; Assigned to Arm(s): Metformin, Standard exercise | Intervention Type: DRUG; Name: Metformin Intensive exercise; Assigned to Arm(s): Metformin, Intensive exercise | Intervention Type: BEHAVIORAL; Name: Placebo Standard exercise; Assigned to Arm(s): Placebo, Standard exercise | Intervention Type: BEHAVIORAL; Name: Intensive exercise; Assigned to Arm(s): Placebo, Intensive exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Based Strategy to Reduce Errors in Diabetes Care
Brief Summary: This project evaluates a HPMG effort to reduce error rates through customized direct feedback of diabetes quality of care data to diabetes patients and their physicians. HPMG has routinely provided patients with personalized feedback of glucose and cholesterol test results since about 1997. This project will implement and evaluate the impact of this intervention on diabetes medical error rates and resource use.


Options:
A: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Case Management | Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Other: Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Case Management, Usual Care
C: Arm Label: Advanced care; Type: OTHER; Interventions: Other: Advanced Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Advanced Care; Assigned to Arm(s): Advanced care
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Based Strategy to Reduce Errors in Diabetes Care
Brief Summary: This project evaluates a HPMG effort to reduce error rates through customized direct feedback of diabetes quality of care data to diabetes patients and their physicians. HPMG has routinely provided patients with personalized feedback of glucose and cholesterol test results since about 1997. This project will implement and evaluate the impact of this intervention on diabetes medical error rates and resource use.


Options:
A: Arm Label: physician chart reminder; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder | Arm Label: chart reminder, educational mat'ls, FIT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder, Behavioral: chart reminder, educational mat'ls, FIT | Arm Label: CR, ed mat'ls, FIT, phone call; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physician chart reminder, Behavioral: CR,ed mat'ls, FIT, phone call | Intervention Type: BEHAVIORAL; Name: Physician chart reminder; Assigned to Arm(s): CR, ed mat'ls, FIT, phone call, chart reminder, educational mat'ls, FIT, physician chart reminder | Intervention Type: BEHAVIORAL; Name: chart reminder, educational mat'ls, FIT; Assigned to Arm(s): chart reminder, educational mat'ls, FIT | Intervention Type: BEHAVIORAL; Name: CR,ed mat'ls, FIT, phone call; Assigned to Arm(s): CR, ed mat'ls, FIT, phone call
B: Arm Label: Safety Training; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Safety Training | Arm Label: Personal Health Partner and Counseling (PHP+C); Type: EXPERIMENTAL; Interventions: Behavioral: Personal Health Partner and Counseling (PHP+C) | Intervention Type: BEHAVIORAL; Name: Safety Training; Assigned to Arm(s): Safety Training | Intervention Type: BEHAVIORAL; Name: Personal Health Partner and Counseling (PHP+C); Assigned to Arm(s): Personal Health Partner and Counseling (PHP+C)
C: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
D: Arm Label: Intervention Condition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Web-Based Intervention | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Web-Based Intervention; Assigned to Arm(s): Intervention Condition

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Based Strategy to Reduce Errors in Diabetes Care
Brief Summary: This project evaluates a HPMG effort to reduce error rates through customized direct feedback of diabetes quality of care data to diabetes patients and their physicians. HPMG has routinely provided patients with personalized feedback of glucose and cholesterol test results since about 1997. This project will implement and evaluate the impact of this intervention on diabetes medical error rates and resource use.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Other: Australian Government Bowel Cancer Screening booklet | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Australian Government Bowel Cancer Screening booklet; Assigned to Arm(s): 3
B: Arm Label: Absolute risk reduction information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Absolute risk reduction | Arm Label: Prolongation of life information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolongation of life | Intervention Type: BEHAVIORAL; Name: Absolute risk reduction; Assigned to Arm(s): Absolute risk reduction information | Intervention Type: BEHAVIORAL; Name: Prolongation of life; Assigned to Arm(s): Prolongation of life information
C: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
D: Arm Label: FOBT by laboratory requisition or directly by PCP; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FOBT by lab req. or directly from PCP + study magnet; Type: EXPERIMENTAL; Interventions: Behavioral: Refrigerator Magnet | Intervention Type: BEHAVIORAL; Name: Refrigerator Magnet; Assigned to Arm(s): FOBT by lab req. or directly from PCP + study magnet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Based Strategy to Reduce Errors in Diabetes Care
Brief Summary: This project evaluates a HPMG effort to reduce error rates through customized direct feedback of diabetes quality of care data to diabetes patients and their physicians. HPMG has routinely provided patients with personalized feedback of glucose and cholesterol test results since about 1997. This project will implement and evaluate the impact of this intervention on diabetes medical error rates and resource use.


Options:
A: Intervention Type: BEHAVIORAL; Name: Education for professionals; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Distribution of educational materials; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Feedback for professionals; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Reminders for professionals; Assigned to Arm(s): N/A
B: Arm Label: Early Feedback Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Publicly released hospital cardiac report cards | Arm Label: Delayed Feedback Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Publicly released hospital cardiac report cards | Intervention Type: BEHAVIORAL; Name: Publicly released hospital cardiac report cards; Assigned to Arm(s): Delayed Feedback Arm, Early Feedback Arm
C: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
D: Arm Label: ATP III; Type: EXPERIMENTAL; Interventions: Behavioral: Palm-Pilot Intervention | Arm Label: JNC 7; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Palm-Pilot Intervention | Intervention Type: BEHAVIORAL; Name: Palm-Pilot Intervention; Assigned to Arm(s): ATP III, JNC 7

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: OAC alone; Type: EXPERIMENTAL; Interventions: Drug: OAC alone | Arm Label: OAC plus single APT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: OAC alone; Assigned to Arm(s): OAC alone
D: Arm Label: 1. YM150 Dose V, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 2. YM150 Dose W, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 3. YM150 Dose X, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 4. YM150 Dose Y, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 5. YM150 Dose Y, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 6. YM150 Dose Z, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 7. Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: YM150; Assigned to Arm(s): 1. YM150 Dose V, twice daily, 2. YM150 Dose W, once daily, 3. YM150 Dose X, twice daily, 4. YM150 Dose Y, once daily, 5. YM150 Dose Y, twice daily, 6. YM150 Dose Z, once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 7. Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
B: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 5mg, Drug: warfarin 1mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2
D: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: SOC; Type: PLACEBO_COMPARATOR; Interventions: Other: Drug therapy for HF | Arm Label: NT-proBNP arm; Type: ACTIVE_COMPARATOR; Interventions: Other: NT-proBNP guided HF therapy | Intervention Type: OTHER; Name: Drug therapy for HF; Assigned to Arm(s): SOC | Intervention Type: OTHER; Name: NT-proBNP guided HF therapy; Assigned to Arm(s): NT-proBNP arm
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Telmisartan, Bisoprolol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan, Bisoprolol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Arm Label: Usual Care; Type: EXPERIMENTAL; Interventions: Other: Usual Care | Arm Label: Biomarker-Guided Care; Type: EXPERIMENTAL; Interventions: Device: Biomarker-guided care NT-proBNP | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care | Intervention Type: DEVICE; Name: Biomarker-guided care NT-proBNP; Assigned to Arm(s): Biomarker-Guided Care

Answer: C